Kiniksa Pharmaceuticals International, plc 8-K

What Happened
Kiniksa Pharmaceuticals International, plc filed a Form 8‑K on January 12, 2026, furnishing a press release that reported unaudited full‑year 2025 commercial results. The company announced ARCALYST net product revenue of $677.5 million for the full year 2025, a gross‑to‑net rate of 8.4% for 2025, and a cash, cash equivalents and short‑term investments balance of $414.1 million as of December 31, 2025. The company also reported having no debt (unaudited).

Key Details

• ARCALYST net product revenue (FY2025, unaudited): $677.5 million.
• Gross‑to‑net for FY2025 (unaudited): 8.4%.
• Cash, cash equivalents and short‑term investments (as of Dec 31, 2025, unaudited): $414.1 million; no debt.
• Information was disclosed via a press release furnished as Exhibit 99.1 to the Form 8‑K filed Jan 12, 2026.

Why It Matters
These figures give investors a snapshot of Kiniksa’s commercial performance (ARCALYST revenue and gross‑to‑net) and liquidity (cash and no debt) at year‑end 2025. Revenue and gross‑to‑net affect reported earnings; a lower gross‑to‑net percentage generally means a higher share of gross sales retained as net revenue. The sizable cash balance and lack of debt suggest financial flexibility for operations and potential investments. All figures cited are unaudited and were provided in the company’s Jan 12, 2026 disclosure.